191 related articles for article (PubMed ID: 32447722)
1. Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis.
Zmira O; Halpern AI; Abraham L; Achiron A
Acta Neurol Belg; 2021 Dec; 121(6):1513-1518. PubMed ID: 32447722
[TBL] [Abstract][Full Text] [Related]
2. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.
Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
Mult Scler Relat Disord; 2023 Jun; 74():104712. PubMed ID: 37054581
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.
López-Real AM; Gonzalez I; Solar DM; Oterino A; Costa E; Pato A; Llaneza MA; García-Estévez DA; Rodriguez-Regal A; Rodriguez M; Peña J
Mult Scler Relat Disord; 2023 Jul; 75():104762. PubMed ID: 37229800
[TBL] [Abstract][Full Text] [Related]
4. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;
J Neurol; 2018 Dec; 265(12):2851-2860. PubMed ID: 30259178
[TBL] [Abstract][Full Text] [Related]
5. Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.
Costa-Frossard França L; Meca Lallana V; Labiano-Fontcuberta A; Blasco R; Monreal E; Martínez Ginés ML; Aguirre C; Sabin Muñoz J; Sainz de la Maza S; Cuello JP; Díaz-Pérez C; Chico García JL; Lozano Ros A; Rodríguez Jorge F; Martínez Martínez S; García Domínguez JM
CNS Drugs; 2024 Mar; 38(3):231-238. PubMed ID: 38418770
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients.
Kim H; Lee EJ; Kim SK; Kim KK; Lim YM
Mult Scler Relat Disord; 2019 May; 30():247-251. PubMed ID: 30849681
[TBL] [Abstract][Full Text] [Related]
7. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
Bose G; Rush C; Atkins HL; Freedman MS
Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
[TBL] [Abstract][Full Text] [Related]
8. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
Alroughani R; Al-Hashel J; Ahmed SF
Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
11. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
[TBL] [Abstract][Full Text] [Related]
12. Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response.
Sovetkina A; Nadir R; Scalfari A; Tona F; Murphy K; Rigoni E; Dorsey R; Malik O; Nandoskar A; Singh-Curry V; Nicholas R; Martin N
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32667988
[TBL] [Abstract][Full Text] [Related]
13. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
Berger T; Elovaara I; Fredrikson S; McGuigan C; Moiola L; Myhr KM; Oreja-Guevara C; Stoliarov I; Zettl UK
CNS Drugs; 2017 Jan; 31(1):33-50. PubMed ID: 27882532
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
Le Page E; Deburghgraeve V; Lester MA; Cardiet I; Leray E; Edan G
J Neurol; 2015; 262(4):1024-34. PubMed ID: 25701008
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center.
di Ioia M; Di Stefano V; Farina D; Di Tommaso V; Travaglini D; Pietrolongo E; Sensi SL; Onofrj M; De Luca G
Mult Scler Relat Disord; 2020 Feb; 38():101504. PubMed ID: 31733426
[TBL] [Abstract][Full Text] [Related]
17. A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis.
Sandgren S; Novakova L; Nordin A; Axelsson M; Malmeström C; Zetterberg H; Lycke J
Front Neurol; 2023; 14():1265354. PubMed ID: 37808497
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.
Tuohy O; Costelloe L; Hill-Cawthorne G; Bjornson I; Harding K; Robertson N; May K; Button T; Azzopardi L; Kousin-Ezewu O; Fahey MT; Jones J; Compston DA; Coles A
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):208-15. PubMed ID: 24849515
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab treatment for multiple sclerosis in Austria: An observational long-term outcome study.
Moser T; Foettinger F; Hitzl W; Novotna B; Berger T; Bsteh G; Di Pauli F; Hegen H; Kornek B; Langenscheidt D; Sellner J
Ann Clin Transl Neurol; 2024 Jun; 11(6):1442-1455. PubMed ID: 38715245
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study.
Brecl Jakob G; Barun B; Gomezelj S; Gabelić T; Šega Jazbec S; Adamec I; Horvat Ledinek A; Rot U; Krbot Skorić M; Habek M
Neurol Sci; 2021 Nov; 42(11):4591-4597. PubMed ID: 33660157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
